Pfizer has issued an RPF for its Gene & Anti-TFPI Therapies in Hemophilia competitive grant program.
Through the program, grants of up to $125,000 a year for up to two years will be awarded in support of projects in the following areas:
Basic Science of Gene Therapy for Hemophilia — Includes basic science, tropism, transduction efficiency, and tolerability of Adeno-associated virus (AAV); AAV antibody seroprevalence, titer- assessment, reduction, and tolerance; role of immunosuppression in managing immune response and potential retreatment; and effect of gene therapy on liver biology.
Basic Science of TFPI and Anti-TFPI Monoclonal Antibodies — Includes basic biology of TFPI interactions with Protein C, ATIII & Protein S; cross talk among regulators (e.g., Protein S being a co-factor for both Protein C and TFPI); role of different TFPI pools in regulation of coagulation; and impact of concomitant treatments (especially antifibrinolytics) added to anti-TFPI on the physiology of hemostasis
Burden of Disease: Clinical Hemophilia A and B — Includes natural history of hemophilia and adherence to current standard of care; arthropathy: presence, development, clinical burden, and joint damage in hemophilia; patient experiences with hemophilia, treatment preferences, and quality of care; and quality of life/work analysis and cost of care in hemophilia.
To be eligible, applicants must be affiliated with a host institution and have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy, physiotherapy, or social work.
See the Pfizer website for complete program guidelines and application instructions.